Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Ciena | Montage Technology | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Ciena's FY2025 10-K describes a technology position that has held but does not lock customers in. On the durable side, the strategy is to "build on and expand our global leadership in optical networking", resting on "our proprietary WaveLogic™ coherent modem technology" and approximately 2,400 issued patents with 800 more pending as of December 2, 2025. On the limiting side, the same filing says competition "remains intense" and features "aggressive selling efforts, including using significant pricing pressure to displace incumbent vendors", that "our customer contracts generally do not include minimum or guaranteed purchases", and that "there is no assurance that we will maintain our incumbency". Concentration cuts the same way: the five largest customers contributed approximately 50% of fiscal 2025 revenue, one cloud provider approximately 18%. Its income statement reports gross profit of $1,878.9M on $4,386.5M of revenue in FY2023, $1,719.6M on $4,015.0M in FY2024 and $2,004.9M on $4,769.5M in FY2025. Self-described leadership in its segments, with customers that are re-won deal by deal, is a narrow moat. | narrow The 2026 interim results announcement (published 2026-08-28) cites Frost & Sullivan that in 2024 'the global memory interconnect chip market was highly concentrated, with the top three players accounting for 93.4% of total revenue; we ranked first globally with a market share of approximately 36.8%', and reports H1 2026 gross margin of 65.3%, up 4.87 percentage points. That is a real and profitable position, but its durability is not established: the 2025 annual report (https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042404088.pdf) warns that 'Early-mover advantages are critical to our ability to capture market share. If competitors launch next-generation products ahead of us during product cycles, we may lose substantial market share', says the DDR5 iteration cycle 'has shortened to 12 to 18 months', and says Samsung Electronics, SK Hynix and Micron Technology 'collectively account for more than 90% of the global server DRAM market'. The lead has to be re-won every sub-generation, in a market whose top three suppliers held 93.4% of 2024 revenue and whose server-DRAM end market three companies hold more than 90% of. And on July 15, 2026 Seoul prosecutors searched the Group's South Korean office in an investigation of a potential competition-law violation (no charges as of the announcement). Narrow, not wide. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The FY2025 10-K locates the advantage in owned technology rather than in customer lock-in: "The success of our business and technology leadership depends significantly on our proprietary and internally developed technology." That technology is centred on WaveLogic, which Ciena's fiscal Q3 2026 earnings presentation (the source of the first two product rows below) defines as "Ciena's proprietary family of coherent optical chips — the core technology inside most of our networking products", and it reaches beyond Ciena's own systems: the 10-K's coherent pluggable transceivers use WaveLogic "for use within our systems and third-party equipment". Switching costs are the weaker candidate, because the same filing describes operators disaggregating line systems from modems and competitors using price to displace incumbents. | efficient scale The filing locates the protection in the cost and time of entry, not in exclusive IP: 'Memory interconnect chips feature high entry barriers in terms of R&D capabilities and technical expertise. New entrants require years of intensive R&D to keep pace with the latest industry standards and product iteration cycles, while also completing stringent product validation and qualification processes', and the chips must 'undergo rigorous qualification processes from server CPU vendors and memory modules manufacturers before they can be deployed at scale in commercial applications'. The products are built to open standards ('Leveraging open industry standards, we have established ourselves as a market leader in memory interconnect'), so rivals can and do build compliant parts; what keeps the field small is a market the report's Frost & Sullivan data estimate at USD1,579 million for 2025, in which the top three held 93.4% of 2024 revenue. Montage's role as JEDEC spec owner of DDR5 RCD, MDB and CKD chips is its head start inside that oligopoly, not a lock that excludes the other two. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Slide 6 of Ciena's fiscal Q3 2026 earnings presentation of 2026-09-03 (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) lists "#1 in Data Center Interconnect Globally" (Dell'Oro Group), "#1 in Total Optical Networking in N. America" (Cignal AI, Dell'Oro Group, Omdia) and "#1 in Submarine Networks Globally" (Omdia), with market share measured as of Q2 2026 excluding China, and a caveat that Ciena "has not independently verified" the analyst data. On the company's own presentation of that data, that is the front rank in its core segments, but the presentation does not claim the global lead in total optical networking, and the FY2025 10-K says competition is "dominated by a small number of very large, multi-national companies" - Nokia, Huawei, Cisco, Hewlett Packard Enterprise and ZTE - many of which have "substantially greater financial, operational and marketing resources, and broader product offerings". A shared front rank, led by Ciena where the company-reported rankings measure it, rather than an uncontested one. | co leader Frost & Sullivan, as cited in the interim announcement, ranks Montage first in 2024 memory interconnect chips at approximately 36.8%, with the top three at 93.4%. The two unnamed rivals therefore out-earn Montage combined, and its margin over second place is not disclosed. The company says it 'maintained our global leadership in the DDR5 generation' and calls itself 'one of the only two suppliers of DDR5 Gen 1 MRCD/MDB chips in the world'. In 2024 PCIe Retimers it is second at around 10.9%, in a market where 'the top two companies captured 96.9%'. It is first by revenue in its core market, but inside a three-way oligopoly rather than clear of it. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate Moderate, and improving. The FY2025 10-K's income statement reports gross profit of $1,878.9M on $4,386.5M, $1,719.6M on $4,015.0M and $2,004.9M on $4,769.5M of revenue for FY2023-FY2025, in a market where, the filing says, rivals use "significant pricing pressure to displace incumbent vendors" and "price and total cost of ownership" heads the list of competitive factors. Since then the AI build-out has lifted gross margin: Ciena's fiscal Q3 2026 earnings presentation (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) reports GAAP gross margin of 45.4% against 41.3% a year earlier, on revenue up 37% year over year, and guides fiscal 2027 adjusted gross margin to 45% to 46%. The presentation does not say how much of that is price rather than mix or volume, and the 10-K warns that AI-related demand has led to "a constrained supply environment" that can raise component costs. | moderate Margins are high and rising. The 2025 annual report (https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042404088.pdf) gives gross margin of 62.2% in 2025 against 58.1% in 2024, and the interim gives 65.3% for H1 2026, with interconnect chips at 69.3%. But the interim attributes the increase 'mainly' to 'the increase in the proportion of sales revenue of products with higher gross profit margin', which is mix, not price. The buyer side is concentrated. The annual report says the five largest customers took 77.2% of revenue and the largest 29.7%, and it warns that 'significant customer pricing demands or intensified competition, may lead to volatility in our market share and a decline in revenue'. Separately, on July 15, 2026 the Fair Trade Investigation Division of the Seoul Central District Prosecutors' Office began a search and seizure at the Group's South Korean office over 'a potential competition law violation'. Per the Group's July 16, 2026 announcement (https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0717/2026071700057.pdf), none of the Group, its directors or employees had been charged. The Standard (https://www.thestandard.com.hk/finance/article/337444/Montage-Technology-shares-drop-229pc-amid-fair-trade-violation-suspicions, 2026-07-16) reports that prosecutors raided Montage, Renesas Electronics and Rambus 'on suspicion of violating fair trade acts and manipulating prices'. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Ciena is the optical-transport specialist among networking vendors - its fiscal Q3 2026 earnings presentation calls it "the only pure-play optical systems provider operating at scale today" - and its FY2025 10-K builds the business on one proprietary technology, the WaveLogic coherent modem, carried into the 6500 Packet-Optical Platform, Waveserver data center interconnect systems, the 6500 RLS photonic line system and coherent pluggable transceivers sold for Ciena's own systems and third-party equipment. Analyst rankings the company cites in that presentation, which it says it "has not independently verified", put Ciena first in data center interconnect globally, in total optical networking in North America and in submarine networks globally (Q2 2026, excluding China). The AI build-out has turned it into more of a cloud supplier than a telecom one: cloud providers were 53% of fiscal Q3 2026 revenue, revenue rose 37% year over year, and GAAP gross margin reached 45.4%. The 10-K is equally clear about why the position is narrow rather than wide. Competition is "dominated by a small number of very large, multi-national companies", many with greater resources; rivals use pricing to displace incumbents; contracts carry no minimum or guaranteed purchases; the five largest customers were about half of fiscal 2025 revenue; and disaggregation lets an operator buy the line system from one vendor and the modem from another, while the push into data-center interconnects brings Ciena up against Marvell, Credo and Broadcom. | Montage is a fabless designer of interconnect chips for servers and PCs: DDR5 memory interface chips (RCD/DB), MRCD/MDB for high-bandwidth MRDIMM modules, CKD clock drivers for PC modules, module supporting chips (SPD, PMIC and TS), PCIe Retimers and CXL MXC memory-expander controllers, plus a smaller Jintide x86 server-CPU line built 'With the x86 cores that we procured from Intel'. Its edge is standards leadership in a concentrated niche. It invented the DDR4 '1+9' buffered architecture that was 'ultimately adopted as a JEDEC international standard', it is JEDEC spec owner of DDR5 RCD, MDB and CKD chips, and Frost & Sullivan, as cited in the interim, ranks it first in 2024 memory interconnect chips at approximately 36.8%, with the top three at 93.4%. It extended into PCIe Retimers on in-house SerDes IP and, on the same Frost & Sullivan data, ranked second in 2024 at around 10.9%, as a self-described new entrant. H1 2026 revenue was RMB3,335 million, up 26.7%, with interconnect-chip gross margin of 69.3%. The weaknesses are structural. Per the 2025 annual report, its direct customers for memory chips are module makers in a server DRAM market that three companies hold more than 90% of, and the five largest customers took 77.2% of 2025 revenue. South Korea accounted for RMB2,925 million of RMB5,456 million in 2025 revenue. And on July 15, 2026 the Seoul Central District Prosecutors' Office searched the Group's Korean office in an investigation of a potential competition-law violation. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Ciena sits between optical-component suppliers and the operators building AI-era networks. Upstream, its FY2025 10-K says its products include "optical and electronic components for which reliable, high-volume supply is often available only from sole or limited sources", built by contract manufacturers with facilities in Canada, Mexico, Thailand, Vietnam and the United States; at November 1, 2025 it carried $826.2 million of inventory and $2.1 billion of purchase commitments. Downstream, the fiscal Q3 2026 earnings presentation puts direct cloud providers at 53% of the quarter's revenue against 37% for service providers, and describes its products as the links between data centers (data center interconnect) and between distributed AI training clusters ("scale-across"). | Upstream fabless chip supplier. Per the 2025 annual report, memory interface and supporting chips go to memory module manufacturers ('our direct customers being memory module manufacturers'), and PCIe Retimers go to server OEMs/ODMs as direct customers, with cloud providers as end users. Wafer fabrication, packaging and testing are outsourced, and the five largest suppliers were 79.4% of 2025 purchases. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. |